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To study whether glucocorticoid (GC) resistance delineates disease-relevant T helper (Th)
subsets that home to the CNS of patients with early MS.
Methods
The expression of key determinants of GC sensitivity, multidrug resistance protein 1 (MDR1/
ABCB1) and glucocorticoid receptor (GR/NR3C1), was investigated in proinflammatory Th
subsets and compared between natalizumab-treated patients with MS and healthy individuals.
Blood, CSF, and brain compartments from patients with MS were assessed for the recruitment of
GC-resistant Th subsets using fluorescence-activated cell sorting (FACS), quantitative poly-
merase chain reaction (qPCR), immunohistochemistry, and immunofluorescence.
Results
An MS-associated Th subset termed Th17.1 showed a distinct GC-resistant phenotype as
reflected by high MDR1 and low GR expression. This expression ratio was further elevated in
Th17.1 cells that accumulated in the blood of patients withMS treated with natalizumab, a drug
that prevents their entry into the CNS. Proinflammatory markers C-C chemokine receptor 6,
IL-23R, IFN-γ, and GM-CSF were increased in MDR1-expressing Th17.1 cells. This subset
predominated the CSF of patients with early MS, which was not seen in the paired blood or in
the CSF from patients with other inflammatory and noninflammatory neurologic disorders.
The potential of MDR1-expressing Th17.1 cells to infiltrate brain tissue was confirmed by their
presence in MS white matter lesions.
Conclusion
This study reveals that GC resistance coincides with preferential CNS recruitment of patho-
genic Th17.1 cells, which may hamper the long-term efficacy of GCs in early MS.
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Early MS is characterized by waves of brain-infiltrating immune
cells that drive inflammation within the CNS, resulting in de-
myelination and eventually neurodegeneration.1 Glucocorticoids
(GCs) are broad-spectrum immunosuppressive drugs that are
used as standard regimen to dampen acute exacerbations inMS.2
Although GCs effectively relieve clinical symptoms, these drugs
do not halt subsequent exacerbations or disease progression.3 Of
interest, blood cells of patients with relapsing-remitting MS
(RRMS) show reduced sensitivity to GCs,4,5 indicating a limited
window of opportunity for inducing long-term efficacy of thisMS
treatment. To achieve this, more insights into the underlying
mechanisms of GC insensitivity are required in early MS.
On binding its ligand, the glucocorticoid receptor (GR/
NR3C1) hyperphosphorylates, forms dimers with other nu-
clear receptors, and translocates into the nucleus.2 Within the
nucleus, these dimers recognize GR elements in promoter
regions or interact with transcription factors to transactivate
or repress proinflammatory gene expression.2 Apart from
binding to the GR, GCs can be excreted out of the cell by the
multidrug resistance protein 1 (MDR1/ABCB1).6
In experimental autoimmune encephalitis (EAE) mice, the ther-
apeutic efficacy of GCs depends on the suppression of CNS
recruitment of proinflammatory CD4+ T helper (Th) cells.7,8
Because GCs are unable to induce long-term protective effects in
MS, it is tempting to speculate that certain pathogenic Th cells
avoid GC-mediated suppression and thereby contribute to re-
current disease activity.9 C-C chemokine receptor 6 (CCR6) ex-
pression onmemory Th cells promotes their recruitment into the
CNS and is essential for the induction of EAE.10,11 In patients with
RRMS, blood-derived CCR6+ and not CCR6− memory Th cells
show increased proinflammatory capacity in response to myelin
peptides.12 Previously, our group revealed that a human patho-
genic CCR6+ Th subset commonly termed Th17.1 (interleukin
(IL)-17lowinterferon (IFN)-γhighgranulocyte-macrophage colony-
stimulating factor (GM-CSF)high) is associated with early
MS.13–17 Of interest, we and others found that Th17.1 cells from
healthy individuals express high levels of ABCB1,13,15 which en-
codes for MDR1 and links to the reduced GC sensitivity found in
patients with RRMS.4
In this study, we addressed howMDR1 and GR are expressed
among memory Th subsets including Th17.1 and whether
this coincides with their potential to infiltrate the CNS of
patients with early MS.
Methods
Patients and sampling
Treatment-naive patients with clinically isolated syndrome and
RRMSwere diagnosed based on theMcDonald 2017 criteria and
included at the MS Center ErasMS, Erasmus MC. We collected
fresh CSF and blood from these patients and patients with
noninflammatory and other inflammatory neurologic diseases
(table 1). Postmortem blood, meninges, and white matter tissues
were obtained from autopsied MS donors (Netherlands Brain
Bank, Amsterdam; table 1) and freshly processed as previously
described.18 Furthermore, blood samples were collected from
patients with RRMS treated with natalizumab for 12 months and
frozen down until further use. The use of primary material and
experimental procedures were approved by the medical ethics
committee of each respective center.
Antibodies and flow cytometry
The anti–human monoclonal antibodies used for flow cytometry
are described in supplementary table 1A (links.lww.com/NXI/
A325). For MDR1 surface staining, cells were taken up in Roswell
Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher
Scientific) containing 2% fetal calf serum and 25 μMcyclosporin A
(Sigma-Aldrich, St Louis, MO), which allows for a conformational
change exposing the epitope19 or absolute ethanol (Merck,
Schiphol-Rijk, TheNetherlands) as a vehicle control. Subsequently,
MDR1 (Biolegend, London, UK) antibody was added, and cells
were incubated for 20 minutes at 37°C and 5% CO2. Cells were
stained using Fixable Viability (L/D) Stain 700 (BD Biosciences,
Erembodegem, Belgium), eFluor 506, or eFluor 520 (Thermo
Fisher Scientific, Landsmeer, The Netherlands) in the dark for 15
minutes at 4°C. Other surface markers were stained in the dark for
30 minutes at 4°C. Cy5.5-Annexin V (BD Biosciences) was added
in the presence of calcium chloride to define early apoptotic
(Annexin V+Live/Dead−) and late apoptotic (Annexin V+Live/
Dead+) memory CD4+ Th cells. Cells were measured using the
LSRII-Fortessa or FACSAria-III flow cytometer and analyzed using
FACSDiva software (Version 8.0.1; BD Biosciences).
Cell sorting
CD4+ cells were isolated from fresh healthy blood donors
(Sanquin, Amsterdam, The Netherlands) using CD4 microbe-
ads and the autoMACS Pro Separator (both Miltenyi Biotec,
Bergisch Gladbach, Germany) and were frozen down until fur-
ther use. After thawing, CCR6+ memory Th populations
(CD3+CD4+CD8−CD25lowCD45RA−CD45RO+) were iso-
lated using a FACSAria-III machine. CCR6+ memory Th
Glossary
CCR6 =C-C chemokine receptor 6; EAE = experimental autoimmune encephalitis; FACS = fluorescence-activated cell sorting;
GC = glucocorticoid; GM-CSF = granulocyte-macrophage colony-stimulating factor; GR = glucocorticoid receptor; HPA =
hypothalamus-pituitary-adrenal; IFN = interferon; IL = interleukin; MDR1 = multidrug resistance protein 1; qPCR =
quantitative polymerase chain reaction; Rh123 = rhodamine 123; RORγt = RAR-related orphan nuclear receptor γt; RPMI
1640 = Roswell Park Memorial Institute 1640 medium; RRMS = relapsing-remitting MS; STAT3 = signal transducer and
activator of transcription 3; T-bet = T-box transcription factor; Th = T helper.
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subsets were further defined based on differential expression of
CXCR3 and CCR4; Th17 (CCR6+CXCR3−CCR4+), Th17
double-positive (“DP”; CCR6+CXCR3+CCR4+) and Th17.1
(CCR6+CXCR3+CCR4−/dim).14 Freeze-thawing effects on
CCR6 and CXCR3 expression are displayed in supplementary
figure 1A (links.lww.com/NXI/A323).
RNA isolation and quantitative PCR
RNA isolation, complementary DNA synthesis, and real-time
quantitative PCRs were performed as previously described.13
Primer-probe sets were designed using the Universal ProbeLi-
brary (Roche Applied Science, Penzberg, Germany). Apart from
IFNG and CSF2, which were measured after Phorbol 12-
myristate 13-acetate and ionomycin stimulation, gene expression
was measured in unstimulated cells.13 An overview of all used
primer sequences can be found in supplementary table 1B (links.
lww.com/NXI/A325). RNA samples containing less than 75 ng
total RNA were excluded from the analysis.
In vitro proliferation and apoptosis assay
CD4+ cells from healthy blood donors were thawed and la-
beled with 0.075 μM CellTrace carboxyfluorescein succini-
midyl ester according to the manufacturer’s instructions
(Thermo Fisher Scientific). After washing, Th17 and Th17.1
memory cells were purified using FACS, as described above.
SortedTh17 andTh17.1 cells were plated at 2.5 × 105 cells/mL
and activated with aCD3/CD28 dynabeads (1:5; Thermo
Fisher Scientific) for 3 days. Cells were cultured in RPMI 1640
supplemented with 1% penicillin/streptomycin (Lonza, Verv-
iers, Belgium), 5% human AB serum (Sanquin), and 75 μM
methylprednisolone sodium succinate (Pfizer, Capelle a/
d IJssel, The Netherlands) or a vehicle control. A similar
concentration is given as IV pulse therapy to dampen acute MS
relapses.20 To compare differences in proliferation, the fre-
quencies of viable, carboxyfluorescein succinimidyl ester-
negative cells were analyzed using flow cytometry. For the
apoptosis assay, CD4+ cells were plated out, activated, and
exposed to methylprednisolone in a similar manner as de-
scribed above. As a positive control for apoptosis induction, 1 ×
106 healthy donor peripheral blood mononuclear cells were
exposed to a temperature of 65°C for 20 minutes, put on ice,
and mixed with the same amount of nonexposed cells.
Rhodamine efflux and MDR1 shift assay
We combined a rhodamine 123 (Rh123) efflux and MDR1
shift assay to measure both the efflux potential and MDR1
expression of each Th17 subset.15,19 Peripheral blood mono-
nuclear cells were thawed and resuspended in RPMI 1640
containing 2% fetal calf serum. Cells were resuspended at a
concentration of 1 × 107 cells/mL and were incubated with
Rh123 (0.5 μg/mL) or a vehicle control (ethanol; both Sigma-
Aldrich) in the dark and on ice for 30 minutes. Cells were
Table 1 Patient characteristics
Peripheral blood Ex vivo analysis In vitro analysisa
Cohort HC RRMS, NTZ treatedb,c HC RRMS, NTZ treatedb,c
Individuals, n 9 18 5 11
Females, n (%) 4 (44) 13 (72) 3 (60) 8 (72)
Age in years, median (range)d 47 (23–53) 36 (19–53) 46 (29–62) 36 (19–49)
Disease duration in months, median (range)e NA 100 (12–202) NA 59 (12–151)
CNS compartment CSF, ex vivo Brain/meninges, ex vivo Brain tissue, in situ
Cohort CISb,f RRMSb,f NIND/OINDg,f MS (postmortem) MS (postmortem)
Patients, n (paired blood) 4 (4) 11 (10) 8 (4) 8 (5) 3
Females, n (%) 2 (50) 5 (45) 5 (63) 6 (86) 2 (67)
Age in years, median (range)d 38 (25–42) 32 (18–40) 57 (26–68) 65 (51–70) 49 (48–58)
Follow-up time in months, median (range) 11 (1–22) 6 (2–56) NA NA NA
Disease duration in months, median (range)e 3 (0–4) 3 (0–55) NA NA NA
PMD in hours, median (range)h NA NA NA 7:08 (5:10–8:20) 09:20 (08:30–10:45)
Abbreviations: CIS = clinically isolated syndrome; HC = healthy control; MDR1 = multidrug resistance protein 1; NA = not applicable or available; NIND =
noninflammatory neurologic disease; NTZ = natalizumab; OIND = other inflammatory neurologic diseases; PMD = postmortem delay; RRMS = relapsing-
remitting MS.
a Rhodamine efflux and MDR1 shift assay.
b Diagnosis according to the McDonald 2017 criteria.
c Ex vivo analyses: 11 clinical responders and 7 clinical nonresponders. In vitro analyses: 5 clinical responders and 6 clinical nonresponders.
d At the time of sampling.
e Time from CIS or if applicable RRMS diagnosis to sampling.
f Patients did not receive glucocorticoids before sampling.
g Diagnosis: myelopathy, ulnar neuropathy, neuro-Behçet disease, neurosarcoidosis, B-cell lymphoma, vasculitis, capillary telangiectasia, and neurosyphilis.
h Depicted as hour:minutes.
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washed and supplemented with and without cyclosporin A
(25 μM). Next, MDR1 antibody (supplementary table 1A,
links.lww.com/NXI/A325) was added to all tubes for 2 hours
at 37°C and 5% CO2, after which cells were stained with Th17
subset-defining antibodies as described above. In this way, we
could analyze the efflux potential in one tube (Rh123 without
cyclosporin A) and both the blocking of this efflux and MDR1
surface expression in another tube (Rh123 with cyclosporin A)
for each subset.
In vitro transmigration assay
Memory Th cells (CD3+CD8−CD25lowCD45RA−) were
separated from fresh, MACS-sorted CD4+ cells using FACS.
Trans-endothelial migration was assessed using 5 × 105
memory Th cells and transwell plates coated with a conflu-
ent monolayers of human brain endothelial cells (hCMEC/
D3 cell line) as previously described.13,21,22 Migration was
performed for 4 hours at 37°C and 5% CO2. All experiments
were performed in duplicate. The average percentages of




Immunohistochemistry was performed with an automated,
validated, and accredited staining system Ventana Benchmark
ULTRA using the OptiView Universal DAB Detection Kit
(both VentanaMedical Systems, Oro Valley, AZ). In brief, after
deparaffinization and heat-induced antigen retrieval, 7-μm-
thick brain sections were incubated with the antibody of in-
terest for 32 minutes. This was followed by a hematoxylin II
counter staining for 12 minutes and the addition of a blue
coloring reagent for 8 minutes according to the manufacturer’s
instructions (both Ventana Medical Systems). To assess
MDR1 expression on Th cells, immunofluorescent staining for
MDR1 andCD4was performed using the automatedmultiplex
platform BenchmarkDiscovery (VentanaMedical Systems). In
short, brain sections were deparaffinized and antigen retrieved
with cell conditioning 1 (Ventana Medical Systems) for 32
minutes. Tissue slides were incubated withMDR1 antibody for
32 minutes at 37°C, followed by detection with fluorescein
amidite (Roche Applied Science). Antibody denaturation was
performed using CC2 (Ventana Medical Systems) for 8 mi-
nutes at 100°C. Subsequently, CD4 antibody was incubated for
32 minutes at 37°C, followed by detection with Cy5 (Roche
Applied Science). Finally, slides were washed in phosphate-
buffered saline and mounted with Vectashield containing 4',6-
diamidino-2-phenylindole (Vector laboratories, Peterborough,
UK). For detailed information of the used antibodies, see
supplementary table 1A (links.lww.com/NXI/A325).
Statistical analysis
Statistical tests were performed using GraphPad Prism 5
software and are described in each figure legend. Results are
displayed as individual data points with/without the standard
error of the mean or as a box and whiskers plot. For all tests, a
p value of <0.05 (*) was considered significant.
Data availability
On request from qualified investigators, any acquired data not
published within this article are available. If desired, please
contact the corresponding author of this article.
Results
High ABCB1 and low NR3C1 expression defines
GC-resistant Th17.1 cells with enhanced
proinflammatory capacity
GCsensitivity is determinedby the expressionofABCB1 (MDR1)
and NR3C1 (GR) (figure 1A). Using an MDR1 shift assay, we
found that MDR1 was predominantly expressed on CCR6+ vs
CCR6−memoryTh cells within the bloodof healthy individuals (p
< 0.001; figure 1, B and C), indicating that highMDR1 expression
is not associated with Th1 cells. After subdivision of CCR6+
Th cells into functionally distinct subsets based on CXCR3
and CCR4 expression, MDR1 was abundant on Th17.1
(CCR6+CXCR3+CCR4−/dim; IL-17lowIFN-γhighGM-CSFhigh)
compared with Th17 (CCR6+CXCR3−CCR4+; IL-17highIFN-
γnegGM-CSFdim) and Th17 DP (CCR6+CXCR3+CCR4+; IL-
17dimIFN-γlowGM-CSFdim) cells13,14 from the same blood donors
(p < 0.001 and p < 0.01; figure 1, D and E). Subsequently, we
sorted these populations and analyzed coexpression of MDR1
(ABCB1) with GR (NR3C1). NR3C1 was selectively down-
regulated in Th17.1 cells (p< 0.05; figure 1F), resulting in strongly
elevated ABCB1/NR3C1 expression ratios (p < 0.001; figure 1G).
In vitro experiments confirmed that proliferating Th17.1 cells and
MDR1+ fractions in particular were less sensitive to methylpred-
nisolone compared with paired Th17 cells (figure 1H). This is
probably not related to apoptotic effects because methylprednis-
olone hardly induced early and late apoptosis of memory Th cells
under similar conditions (supplementary figure 2A, links.lww.
com/NXI/A323).23,24 Th17.1-associated genes IL-23 receptor
(IL23R), IFN-γ (IFNG), and GM-CSF (CSF2)13,14 displayed
elevated expression inMDR1+ vsMDR1− fractions ofTh17.1 (p<
0.01 vs p < 0.05, respectively; figure 1I). In contrast to DNAX
accessory molecule 1, expression levels of adhesion molecules
P-selectin glycoprotein ligand 1 and very late antigen 4 were in-
creased on MDR1+ vs MDR1− Th17.1 cells (see supplementary
figure 1B, links.lww.com/NXI/A323). These findings show that
Th17.1 cells have a distinctive GC-resistant phenotype, which
probably contributes to their role in MS disease activity.13
Th17.1 cells trapped in the blood of
natalizumab-treated patients with MS show
increased ABCB1 and reducedNR3C1 expression
In our previous study, Th17.1 cells were found to selectively
accumulate in the blood from patients with MS who clinically
responded to natalizumab treatment.13 This peripheral entrap-
ment makes it possible to analyze the GC resistance profile of
Th17.1 cells that infiltrate the CNS during early MS. After
sorting of these and other CCR6+ memory Th cells from the
blood, we found selectively increased ABCB1 expression in
Th17.1 cells from 11 patients with RRMS who clinically
responded to natalizumab treatment vs 9 age- and sex-matched
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healthy controls (p < 0.05; figure 2A). This was not found in
patients who experienced clinical relapses despite natalizumab
therapy (nonresponders; n = 6; figure 2A). Despite the fact that
all nonresponders were female, sex did not affect expression
profiles within the whole group of patients and controls (data
not shown). NR3C1 was reduced in all CCR6+ Th subsets
analyzed from these patients, which was only significant in
nonresponders and mainly found in Th17.1 (figure 2A). As a
result, ABCB1/NR3C1 expression ratios were enhanced espe-
cially in natalizumab responders compared with healthy controls
(figure 2A). Although the frequencies of MDR1+ Th17.1 cells
were elevated in the responders (p < 0.05), we did not find
Figure 1 High ABCB1 and low NR3C1 expression in Th17.1 cells from healthy blood donors
(A) Simplistic illustration of glucocorticoid regulation within an immune cell. GCs diffuse through the plasma membrane and bind to GR (NR3C1) within the
cytoplasm. On binding, GRs form dimers and translocate into the nucleus to regulate proinflammatory gene expression. However, GCs can also be
transported out of the cell by MDR1 (ABCB1). (B) Representative FACS dot plots with the gating strategy and MDR1 surface expression for thawed CCR6− and
CCR6+ memory Th (CD3+CD4+CD8−CD25−CD45RA−) cells. (C) Frequencies of MDR1-expressing cells within paired CCR6− and CCR6+ memory Th cells from
healthy blood donors (n = 6). Data were compared using paired t tests. (D and E) Representative gating, percentages, andmedian fluorescence intensity (MFI)
of MDR1 expression for MDR1-expressing cells within each CCR6+ Th subset. Cells were obtained from 6 healthy blood donors and analyzed using a 1-way
analysis of variance (ANOVA)with aNewman-Keulsmultiple comparison test. Relative expression ofNR3C1 (F) and their ABCB1/NR3C1 ratios (G) were analyzed
for paired Th17, Th17 DP, and Th17.1 cells using qPCR (n = 7–8). Data were compared using a repeated measurement 1-way ANOVA with a Newman-Keuls
multiple comparison test. (H) In vitro effects of methylprednisolone (MP; 75 μM) on the proliferation of Th17 and Th17.1 cells (left) and MDR1− and MDR1+
fractions of Th17.1 (right) of 6 healthy blood donors. The percentage of CSFE-labeled cells was compared with vehicle controls after anti-CD3/CD28
stimulation for 3 days. Data were compared using paired t tests. (I) IL23R (IL-23 receptor), IFNG (IFN-γ), and CSF2 (GM-CSF) expression relative to 18S in paired
MDR1+ vsMDR1− Th17.1 cells from 6 to 8 healthy donors. Data were analyzed usingWilcoxon and paired t tests. *p < 0.05, **p < 0.01, ***p < 0.001. CCR6 = C-C
chemokine receptor 6; GC = glucocorticoid; GR = glucocorticoid receptor; MDR1 = multidrug resistance protein 1; Th = T helper.
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differences in MDR1 surface expression (supplementary figure
1C, links.lww.com/NXI/A323) or Rh123 dye efflux (figure 2, B
and C) for Th17.1 cells between these groups. CSF-homing
marker CCR6 was higher expressed on MDR1+ vs MDR1−
Th17.1 cells from the blood of natalizumab-treated patients with
MS (p < 0.0001), which was not seen for CXCR3 (figure 2D).
These data show that GC-resistant Th17.1 cells have a pheno-
type associated with preferential recruitment to the CSF in
early MS.
MDR1+ Th17.1 cells are enriched in the CSF of
patients with earlyMS and not in patients with
other neurologic disorders
Ex vivo flow cytometric analysis of paired blood and CSF
samples from treatment-naive patients with early MS (n = 9,
table 1) revealed a significant rise in MDR1-expressing CD4+
(p < 0.0001) and not CD8+ T memory cells, resulting in
increased CD4/CD8 ratios (p < 0.001) within the CSF
(figure 3A). CCR6-expressing memory Th cells were in-
creased in paired CSF vs blood samples from patients with
early MS (p < 0.0001; supplementary figure 1D, links.lww.
com/NXI/A323) and expressed higher surface levels of
MDR1 than CCR6− memory fractions in MS CSF (p <
0.0001; figure 3B). Th17.1 predominated the CSF of patients
with early MS compared with Th17 and Th17 DP cells (n =
15, table 1 and p < 0.001, figure 3C). This selective enrich-
ment was not found in paired blood samples or in the CSF of
8 patients with other inflammatory or noninflammatory
neurologic disorders (table 1 and figure 3C). The pre-
dominance of Th17.1 cells in early MS CSF was even more
apparent when analyzing MDR1-expressing proportions (p <
0.001; figure 3D). Within the blood of these patients, CCR6
and not CXCR3 was enriched on MDR1+ compared with
MDR1− Th17.1 cells (p < 0.0001 and p < 0.01; figure 3E).
MDR1+ Th17.1 cells in the CSF showed higher CXCR3 levels
than their counterparts in the blood (p < 0.05; figure 3E). The
enhanced recruitment of MDR1+ Th17.1 cells to early MS
CSF shows that this subset preferentially migrates across
blood-CNS barriers, which was confirmed in vitro (supple-
mentary figure 2B and C, links.lww.com/NXI/A323).
MDR1-expressing CD4+ T cells are recruited to
MS brain tissue and show a Th17.1 phenotype
To study whether MDR1high Th17.1 cells also infiltrate the
inflamed MS brain, we first performed in situ analyses of
postmortem white matter tissues from 3 late-stage MS do-
nors showing a high number of perivascular infiltrates. Im-
munohistochemical analysis for MDR1 and CD4 revealed
their coexistence in perivascular areas of active lesions
(figure 4, A and B). Besides the expected presence of MDR1
in other CNS-resident cells,25 we were able to validate the
coexpression of MDR1 with CD4 using confocal micros-
copy (figure 4C). To address how MDR1 was expressed
among MS brain-infiltrating CCR6+ Th subsets, we ana-
lyzed ex vivo single-cell suspensions of postmortem blood,
meninges, and white matter tissues from 8 late-stage MS
donors using flow cytometry (figure 4, D and E). Although a
trend increase was seen for the amount of CCR6+ memory
Th cells in the brain and meninges compared with blood,
this was not significant (Supplementary figure 1E, links.lww.
com/NXI/A323). CXCR3+ memory Th cells were enriched
in brain vs meningeal and blood samples and showed
highest MDR1 expression in brain tissues (p < 0.05; Sup-
plementary figure 1F, links.lww.com/NXI/A323). CD8+
memory T cells showed a similar trend, yet not significant
(Supplementary figure 1G, links.lww.com/NXI/A323). In
contrast to Th17 and Th17 DP cells, frequencies of MDR1+
Th17.1 cells were significantly increased in brain tissue
compared with meninges (p < 0.05) and blood (p < 0.0001;
both figure 4E). Although not significant, Th17.1 also
seemed to be more present in the meninges than in the
blood and were more abundant than Th17 DP cells in brain
tissues. Overall, these findings support the use of MDR1 as a
marker to delineate CNS-homing, potentially pathogenic
Th cells in patients with early MS.
Discussion
CSF from patients with early MS is characterized by increased
numbers of CD4+ and not CD8+ T cells.18,26 Because GCs are
used to dampen acute MS relapses, we examined GC re-
sistance features among different pathogenic CD4+ Th cell
subsets during early MS. Our results demonstrate that Th17.1
cells display a unique GC-resistant (ABCB1highNR3C1low)
phenotype, which is accompanied by a selective enrichment in
the CSF from patients with early MS and not in patients with
other neurologic diseases. The fact that this potentially GC-
resistant Th subset is also localized inMS white matter lesions
puts Th17.1 cells and particularly MDR1 forward as a
promising target for predicting and boosting GC treatment
efficacy in early MS.
Several factors may be responsible for the selective upregu-
lation of ABCB1 (MDR1) and downregulation of NR3C1
(GR) in Th17.1 cells. A pathogenic feature of MS is chronic
activation of the hypothalamus-pituitary-adrenal (HPA) axis,
resulting in elevated levels of the natural GC cortisol.5 Be-
cause GCs can also upregulate MDR127 and downregulate
GR,28–30 such increased levels may trigger GC-resistant,
brain-homing Th17.1 cells in MS. Chronic inflammation was
also found to upregulate MDR1 expression on lymphocytes
via activation of signal transducer and activator of transcrip-
tion 3 (STAT3) protein.31 Consistently, STAT3 drives the
expression of RAR-related orphan nuclear receptor γt
(RORγt), which inhibits GC action32 and is highly abundant
in Th17.1 cells.13 This probably also explains our finding that
the MDR1+ subset of Th17.1 expresses high levels of GM-
CSF, which is directly controlled by RORγt.33 Of note, ste-
roid receptor coactivators, which control GR responses,34
have been recently linked to RORγt-dependent pathogenic
Th17 differentiation.35 In addition, IL-2 is not only an im-
portant trigger of GM-CSF in Th memory cells from patients
with MS36 but is also able to reduce GR expression.37 In EAE,
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Figure 2 Increased frequencies ofMDR1+Th17.1 cells in the blood of natalizumab-treated patientswithMS comparedwith
healthy controls
(A) ABCB1, NR3C1, and ABCB1/NR3C1 expression ratios for Th17, Th17 DP, and Th17.1 cells from thawed peripheral blood mononuclear cells of patients with
MSwho clinically responded (n = 10–11) or did not respond (n = 5–7) to natalizumab treatment and age- and sex-matchedhealthy controls (n = 6–9). Datawere
analyzed using Kruskal-Wallis tests. (B) Representative FACS plot showing Rh123 efflux in Th17, Th17 DP, and Th17.1 cells. (C) Frequencies of MDR1+ Th17,
Th17 DP, and Th17.1 cells within Th cells (top) and percentages of Rh123-negative cells within each subset (bottom) for 11 natalizumab-treated patients with
MS and 5 healthy controls. Data were compared using Kruskal-Wallis tests. (D). CCR6 and CXCR3 expression (MFI) on MDR1− vs MDR1+ Th17.1 cells from 11
natalizumab-treated patients with MS. Data were analyzed using paired t tests. *p < 0.05, **p < 0.01, ****p < 0.0001. HC = healthy control; MDR1 =multidrug
resistance protein 1; NR = did not respond; NTZ= natalizumab; R = responded; Rh123 = rhodamine 123; Th = T helper.
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macrophage migration inhibitor factor induced GC resistance
of Th cells via upregulation of T-box transcription factor
(T-bet),38 another Th17.1-associated transcription factor.13
In parallel with this, we found that T-bet-dependent IFN-γ
was upregulated in MDR1+ Th17.1 cells. Together, these
studies indicate that the GC-resistant phenotype of Th17.1
may be induced by combined effects of a hyperactive HPA axis
and chronic inflammation in patients with MS.
For MDR1, transcript levels were selectively increased in
Th17.1 cells that accumulated in the blood from clinical re-
sponders to natalizumab. This also corresponds to the in-
creased very late antigen 4 expression on MDR1+ vs MDR1−
Th17.1 cells. MDR1 surface expression was not increased on
Th17.1 cells from responders. One limitation of this study is
that we did not analyze total protein levels of MDR1, which
could explain this discrepancy. Furthermore, posttranslational
Figure 3 Selective enrichment of MDR1+Th17.1 cells in the CSF of treatment-naive patients with early MS
(A) Percentages and ratios of MDR1-expressing CD4+ and CD8+memory fractions within CD3+ T cells in fresh blood and CSF samples from patients with early
MS (n = 9). Data were analyzed using paired t tests. (B) Percentages of MDR1-expressing cells within paired CCR6− and CCR6+ memory Th cells from early MS
CSF samples (n = 9). Data were analyzed using paired t tests. (C) Top panel: percentages of CCR6+ subsets within thememory Th pool in the blood (left panel, n
= 14) andCSF (right panel, n = 15) of patientswith earlyMS. Bottompanel: same itemsdisplayed for patientswithNINDorOIND (see table 1; n = 4 for blood and
n = 8 for CSF). Data were compared by a repeated measurement 1-way ANOVA with a Newman-Keuls multiple comparison test. (D) Percentages of MDR1+
CCR6+ Th subsets in the CSF (left) and MDR1+ Th17.1 frequencies in the CSF vs blood (right) from patients with early MS (n = 9–10). Data sets were analyzed
using a 1-way ANOVA with a Newman-Keuls multiple comparison test and a paired t test, respectively. (E) CCR6 and CXCR3 expression levels (MFI) on paired
MDR1+ vsMDR1− Th17.1 cells frompatientswith earlyMS (n = 7). (E) CXCR3 expression (MFI) on CSF- and blood-derivedMDR1+ Th17.1 cells frompatientswith
early MS (n = 7). (E) Data were analyzed using paired t tests. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. CCR6 = C-C chemokine receptor 6; MDR1 =
multidrug resistance protein 1; NIND = noninflammatory neurologic disease; OIND = other inflammatory neurologic disease; Th = T helper.
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regulation of MDR1 such as altered intracellular trafficking and
localization may be different, especially after induction by
cyclosporin A.39 For GR, expression levels were downregulated
in all CCR6+ Th subsets from the blood of natalizumab re-
sponders and were further reduced in nonresponders. A pos-
sible explanation for this is that HPA axis hyperactivity is more
pronounced in patients with progressive MS such as patients
not responding to natalizumab, thus decreasing GR levels.40
Another limitation of this study is that the frequencies and
phenotype of Th17.1 were not analyzed before natalizumab
treatment, which possibly differs between responders and
nonresponders. GR can also be alternatively controlled post-
transcriptionally, but remains a challenge to detect at the pro-
tein level, let alone in distinct Th subsets.
Figure 4 Presence of MDR1+Th17.1 cells in postmortem white matter tissue of patients with MS
Representative immunohistochemical staining for CD4 and MDR1 (A) as well as human leukocyte antigen II (HLA-II), myelin oligodendrocyte glycoprotein
(MOG), microtubule-associated protein 2 (MAP2) (B) in formalin-fixed, paraffin-embeddedwhitematter lesions of 3MS donors. Images were taken with a ×20
digital magnification, and lesions were classified as active and postdemyelinating (MS-1), active and demyelinating (MS-2), and mixed active/inactive and
demyelinating (MS-3).48 (C) Coexpression of CD4 (red) and MDR1 (green) in 4',6-diamidino-2-phenylindole (blue)-positive cells in these brain tissues, as
determined by immunofluorescence staining. (D) Representative gating of ex vivo CCR6+ Th subsets andMDR1+ fractions of Th17.1 (CCR6+CXCR3+CCR4−/dim)
in the blood, meninges, and brain tissue from the same MS donor. (E) Frequencies of MDR1+ Th17, Th17 DP, and Th17.1 cells in freshly isolated single-cell
suspensions from postmortem blood, meninges, and brain tissues from 8 late-stage MS donors, as determined by FACS. A total of 14 brain tissues from 8
donorswere analyzed. Datawere compared using a nonrepeatedmeasurement 2-way ANOVAwith a post hoc Bonferronimultiple comparison test. *p < 0.05
and ****p < 0.0001. MDR1 = multidrug resistance protein 1; Th = T helper.
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Apart from the role of MDR1 and GR in GC resistance, both
molecules also play a critical role in the induction of neu-
roinflammation. Increased GR signaling in pathogenic
T cells protects from CNS autoimmunity, whereas deletion
of GR abrogates this phenomenon in EAE.8,41 Deletion of
ABCB1 resulted in a similar protective phenotype.42 These
studies at least suggest that the low GR and high MDR1
expression in brain-homing Th17.1 drives neuro-
inflammation. Quantification of in situ localization of
MDR1+ Th cells also for patients with other neurologic
diseases should be performed to better interpret their role in
MS brain pathology. Because of their involvement in GC
resistance and local inflammation, MDR1 and GR are
promising targets to improve GC efficacy in early MS. The
need for improving this efficacy is underlined by the in-
creased MDR1-mediated efflux ratio of methylpredniso-
lone,43 the standard treatment of acute MS relapses.
A recent study showed that low vitamin D levels are associated
with GC-resistant relapses in patients with MS.20 Although
controversial results were obtained from clinical trials with re-
spect to disease activity, increasing vitamin D levels improved
GC efficacy and suppressed EAE induction in mice via Th-cell
intrinsic upregulation of NR3C1.20 Because vitamin D also
downregulates CCR6 on Th cells,17 this steroid hormone may
be exploited to enhance GC efficacy in MS by sensitizing
Th17.1 cells. MDR1 activity can also be blocked by other types
of steroids44 and even by anti-CD20 antibodies.45 The selective
targeting of MDR1 is further supported by its additional role in
proinflammatory cytokine excretion46 and trafficking47 of
T cells across the blood-brain barrier. However, the imple-
mentation of such strategies should also be taken with care
because MDR1 is expressed by many other cell types. In-depth
analysis of Th17.1 cells by currently available single-cell plat-
forms would reveal additional targets that can be used for the
design of small-molecule therapeutics. The predominance of
Th17.1 in the CSF of patients with early MS could set the stage
for its use as a marker to predict disease activity.
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